Positiv
●
Proactive Investors
●
vor 3 Monaten
The US Food and Drug Administration has approved a higher-dose version of Spinraza, a key therapy from Biogen Inc (NASDAQ:BIIB, XETRA:IDP) for spinal muscular atrophy (SMA), a move analysts at Jefferies say could help sustain the company's long-standing position in the rare disease market. According to the analysts, the decision was largely anticipated by investors despite earlier regulatory de...